Acceleron Reports First Quarter 2020 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acceleron Pharma (XLRN) Misses Q1 EPS by 9c
May 11, 2020 4:25 PM EDTAcceleron Pharma (NASDAQ: XLRN) reported Q1 EPS of ($0.95), $0.09 worse than the analyst estimate of ($0.86).
Acceleron is off to a strong start in 2020, propelled by one of the most eventful time periods in the Companys history, said Habib Dable, President and Chief Executive Officer of Acceleron. The breadth and depth of our hematology program has been on full display, owing to the publication... More
